Heartburn refractory to proton-pump inhibitors

Current Treatment Options in Gastroenterology

Volumn 10, Issue 1, 2007, Pages 47-56

  Trivedi, Apurva ^a   Long, John D ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIHYPERTENSIVE AGENT; BACLOFEN; BILIRUBIN; CENTRAL DEPRESSANT AGENT; CIMETIDINE; CITALOPRAM; ESOMEPRAZOLE; FLECAINIDE; IBUPROFEN; IMIPRAMINE; LANSOPRAZOLE; LEVODOPA; LITHIUM; MONOAMINE OXIDASE INHIBITOR; OMEPRAZOLE; PHENOTHIAZINE; PLACEBO; PROPAFENONE; PROTON PUMP INHIBITOR; QUINIDINE; RANITIDINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; ANTIREFLUX OPERATION; CLINICAL EXAMINATION; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DIAGNOSTIC TEST; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DROWSINESS; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOSCOPIC SURGERY; ESOPHAGOSCOPY; ESOPHAGUS PH; FATIGUE; FLATULENCE; GASTROESOPHAGEAL REFLUX; HEART ARRHYTHMIA; HEART BLOCK; HEARTBURN; HUMAN; HYPOTENSION; HYPOVOLEMIA; IMPEDANCE; INDIVIDUALIZATION; LAPAROSCOPIC SURGERY; LASSITUDE; LOW DRUG DOSE; MYALGIA; NAUSEA; ORTHOSTATIC HYPOTENSION; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT SELECTION; RADIOFREQUENCY RADIATION; REVIEW; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; STOMACH FUNDOPLICATION; SYMPTOM; SYNCOPE; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VATER PAPILLA STENOSIS; WEAKNESS; WEIGHT GAIN; XEROSTOMIA;

EID: 33847674943     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-007-0056-5     Document Type: Review

References (37)

1. Locke GR 3rd, Talley NJ, Fett SL, et al.: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmstead County, Minnesota. Gastroenterology 1997, 112:1448-1456.
2. Barlow WJ, Orlando RC: The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology 2005, 128:771-778.
3. Fass R, Shapiro M, Dekel R, Sewell J: Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment Pharmacol Ther 2005, 22:79-94.
4. Castell DO, Kahrilas PJ, Richter JE, et al.: Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002, 97:575-583.
5. Dean BB, Gano AD, Knight K, et al.: Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004, 2:656-664.
6. The Gallup Organization: Gallup study of consumers' use of stomach relief products. Princeton, NJ: The Gallup Organization; 2000.
7. Egan LJ, Myhre GM, Mays DC, et al.: CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: Variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment Pharmacol Ther 2003, 17:1521-1528.
8. Peghini PL, Katz PO, Bracy NA, Castell DO: Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998, 93:763-767.
9. Nzeako UC, Murray JA: An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Aliment Pharmacol Ther 2002, 16:1309-1316.
10. Galmiche JP, Clouse RE, Balint A, et al.: Functional esophageal disorders. Gastroenterology 2006, 130:1459-1465.
11. Sgouros SN, Bergele C, Mantides A: Eosinophilic esophagitis in adults: a systematic review. Eur J Gastroenterol Hepatol 2006, 18:211-217.
12. Kahrilas PJ, Quigley EM: Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology 1996, 110:1982-1996.
13. Tack J, Koek G, Demedts I, et al.: Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004, 99:981-988.
14. Bautista JM, Wong WM, Pulliam G, et al.: The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications. Dig Dis Sci 2005, 50:1909-1915.
15. Charbel S, Khandwala F, Vaezi MF: The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005, 100:283-289.
16. Mainie I, Tutuian R, Shay S, et al.: Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy. A multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006, 55:1398-1402.
17. Fass R, Murthy U, Hayden CW, et al.: Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastrooesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000, 14:1595-1603.
18. Fass R, Sontag SJ, Traxler B, Sostek M: Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol 2006, 4:50-56.
19. Fackler WK, Ours TM, Vaezi MF, Richter JE: Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002, 122:625-632.
20. Ours TM, Fackler WK, Richter JE, Vaezi MF: Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003, 98:545-550.
21. Lidums I, Lehmann A, Checklin H, et al.: Control of transient lower sphincter relaxations and reflux by the GABA (B) agonist baclofen in normal subjects. Gastroenterology 2000, 118:7-13.
22. Zhang Q, Lehmann A, Rigda R, et al.: Control of transient lower oesophageal sphincter relaxations and reflux by the GABA (B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 2002, 50:19-24.
23. Vela MF, Tutuian R, Katz PO, Castell DO: Baclofen decreases acid and non-acid post-prandial gastrooesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003, 17:243-251.
24. Koek GH, Sifrim D, Lerut T, et al.: Effect of the GABA (B) agonist baclofen in patients with symptoms of duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003, 52:1397-1402.
25. Degen L, Petrig C, Studer D, et al.: Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil 2005, 17:821-826.
26. Tutuian R, Mainie I, Allan R, et al.: Effects of a 5-HT (4) receptor agonist on oesophageal function and gastro-oesophageal reflux: studies using combined impedance-manometry and combined impedance-pH. Aliment Pharmacol Ther 2006, 24:155-162.
27. Kahrilas PJ, Quigley EM, Castell DO, Spechler SJ: The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000, 14:1503-1509.
28. Rodriguez-Stanley S, Zubaidi S, Proskin HM, et al.: Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity. Clin Gastroenterol Hepatol 2006, 4:442-450.
29. Prakash C, Clouse RE: Long-term outcome from tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci 1999, 44:2373-2379.
30. Varia I, Logue E, O'Connor C, et al.: Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J 2000, 140:367-372.
31. Gorelick AB, Koshy SS, Hooper FG, et al.: Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998, 275:G460-G466.
32. Peghini PL, Katz PO, Castell DO: Imipramine decreases oesophageal pain perception in human male volunteers. Gut 1998, 42:807-813.
33. Broekaert D, Fischler B, Sifrim D, et al.: Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2006, 23:365-370.
34. Arts J, Tack J, Galmiche JP: Endoscopic antireflux therapies. Gut 2004, 53:1207-1214.
35. Arts J, Lerut T, Rutgeerts P, et al.: A one-year follow-up study of endoluminal gastroplication (Endocinch) in GERD patients refractory to proton pump inhibitor therapy. Dig Dis Sci 2005, 50:351-356.
36. Campos GM, Peters JH, DeMeester TR, et al.: Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg 1999, 3:292-300.
37. Swoger J, Ponsky J, Hicks DM, et al.: Surgical fundoplication in laryngopharyngeal reflux unresponsive to aggressive acid suppression: a controlled study. Clin Gastroenterol Hepatol 2006, 4:433-441.